Clinical trial · Observational
Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy
Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy: Construction and Feasibility Study
NCT04048252CI-TRIAL-00103505PROSTEDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The development of a personalized therapeutic education program dedicated to patients with metastatic prostate cancer and receiving next-generation hormone therapy would improve their knowledge of the disease, medication adherence and quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Focus group creation | Other | — | UNRESOLVED |
| Workshop | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Focus group
- interventionNames
- Other: Focus group creation
- label
- Workshop
- interventionNames
- Other: Workshop
Primary outcomes (3)
- measure
- Create a focus group
- timeFrame
- Day 0
- description
- Transcribe interview and mark key points
- measure
- Patient satisfaction
- timeFrame
- End of workshops (max 2 months)
- description
- Yes/no
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate for at least 3 months * The patient must have given their free and informed consent and signed the consent form * The patient must be insured or the beneficiary of an insurance policy Exclusion Criteria: * The subject is not in a fit state to express their consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship
References
Publications (1)
- RESULTCuenant A, Eglin I, Ferreira V, Houede N. [Development of a therapeutic education program for prostate cancer patients undergoing new generation hormone therapy]. Bull Cancer. 2022 May;109(5):623-629. doi: 10.1016/j.bulcan.2021.11.014. Epub 2022 Jan 10. French. PMID 35027162